From: Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma
 | Overall survival | Disease-free survival | ||||
---|---|---|---|---|---|---|
 | HR | 95% C.I. | p -value | HR | 95% C.I. | p -value |
Vascular invasion | 1.39 | 1.14-1.70 | < 0.01 | 1.15 | 0.94-1.40 | 0.18 |
Satellite lesions | 1.23 | 1.03-1.47 | 0.03 | 1.17 | 0.97-1.40 | 0.10 |
Rupture | 1.53 | 0.98-2.40 | 0.06 | 1.21 | 0.76-1.91 | 043 |
Cirrhosis | 0.90 | 0.66-1.21 | 0.47 | 0.96 | 0.70-1.30 | 0.80 |
Encapsulation | 0.67 | 0.49-0.91 | 0.01 | 0.73 | 0.53-0.99 | 0.04 |
Grade (III, IV vs. I, II) | 1.02 | 0.98-1.14 | 0.71 | 1.05 | 0.94-1.17 | 0.42 |
Albumin | 0.97 | 0.64-1.47 | 0.88 | 0.75 | 0.49-1.14 | 0.17 |
AST (> 68 vs. ≤ 68 U/L) | 1.84 | 1.30-2.61 | < 0.01 | 1.65 | 1.14-2.40 | 0.01 |
Bil (> 1.3 ≤ vs. ( 1.3 mg/dL) | 1.40 | 0.89-2.02 | 0.16 | 0.98 | 0.64-1.14 | 0.91 |
AFP (200 ng/mL) | 1.44 | 1.05-1.98 | 0.02 | 1.28 | 0.94-1.75 | 0.123 |
Blood loss (> 0.5 L) | 1.85 | 1.36-2.53 | < 0.01 | 1.43 | 1.05-1.94 | 0.03 |
Margin involved | 0.84 | 0.63-1.12 | 0.29 | 0.78 | 0.59-1.04 | 0.09 |